Did You Know...
...In 1790, the cost to obtain a patent was between $4 and $5.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120045430 | DENDRIMER-LIKE MODULAR DELIVERY VECTOR Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, ca... | 02/23/2012 |
| 20120003277 | NANOEMULSION VACCINES The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides nanoemulsion compositions harboring one or more immunogens within the oil phase of the nanoemulsion and methods of using the sam... | 01/05/2012 |
| 20120003269 | Compositions Produced Using Enteric Pathogens and Methods of Use The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such E. coli or Salmonella. Examples of Salmonella strains that can be used include, for instance, S. e... | 01/05/2012 |
| 20110300179 | Novel Compositions and Uses Thereof The present invention provides a cellular vaccine for therapeutic or prophylactic treatment of a pathological condition, the vaccine comprising or consisting of a population of CD 4+ T cells modified such that they contain an antigenic component, and/or a nucleic acid m... | 12/08/2011 |
| 20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically accepta... | 12/01/2011 |
| 20110256181 | RECOMBINANT BACTERIUM CAPABLE OF ELICITING A PROTECTIVE IMMUNE RESPONSE AGAINST C. PERFRINGENS The present invention encompasses recombinant bacteria and immunogenic compositions comprising the bacteria. The immunogenic composition may be used to induce an immune response against C. perfringens. ... | 10/20/2011 |
| 20110257458 | METHOD OF USING TUMOR CELL DEBRIS TO REDUCE BRAIN TUMOR RECURRENCE OR GROWTH The present invention describes compositions comprising tumor cell debris, tumor lysate or tumor antigens and methods of using tumor cell debris, tumor lysate or tumor antigens for stimulating a specific immune response. The compositions may further comprise at least on... | 10/20/2011 |
| 20110243988 | Methods and Compositions for Stabilization of a Virus Vaccine This invention provides compositions and methods for stabilizing a live attenuated virus in dried formulations. In particular, compositions and methods of preparing a dried vaccine are provided that stabilize the viability of live vaccines such as measles and adenovirus... | 10/06/2011 |
| 20110229515 | IDENTIFICATION OF GENES A method for identifying a microorganism having a reduced adaptation to a particular environment comprising the steps of:
| |
| 20110223195 | COMPOSITION COMPRISING CHITOSAN FOR OCULAR ADMINISTRATION OF VACCINE(S) TO AVIANS The invention relates to vaccine compositions comprising chitosan and a vaccine which are administered to avian species via the ocular route, and methods or programs of vaccination including use of chitosan in order to increase or enhance cell-mediated immunity in avian... | 09/15/2011 |
| 20110206717 | NON-TYPHOIDAL SALMONELLA VACCINES OmpD of non-typhoidal Salmonella (NTS), e.g. as derivable from Salmonella Typhimurium, and immunogenic fragments thereof are proposed for use in treating or preventing NTS infection and/or disease. OmpD of S. paratyphi and fragments thereof are also... | 08/25/2011 |
| 20110206733 | Immunizing Compositions and Methods of Use The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also... | 08/25/2011 |
| 20110206699 | Methods for the Treatment of Graft-Versus-Host Disease Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist suc... | 08/25/2011 |
| 20110200616 | Immunizing Compositions and Methods of Use The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also... | 08/18/2011 |
| 20110200637 | Immunizing Compositions and Methods of Use The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also... | 08/18/2011 |
| 20110189231 | Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines Adjuvants comprising OmpC porin, OmpF porin, or a combination thereof, are provided. The adjuvants can be administered to a subject in combination with antigenic material in order to potentiate the immunogenic effect of the antigenic material. Also provided are products... | 08/04/2011 |
| 20110182847 | USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxi... | 07/28/2011 |
| 20110182939 | Vaccine Adjuvants The invention provides novel adjuvants and pharmaceutical composition comprising of an adjuvant alone. The invention also provides novel vaccine compositions comprising of an antigen and a novel adjuvant. The novel adjuvant as per present invention is farnesoid-X-recept... | 07/28/2011 |
| 20110159026 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO FLAGELLATED BACTERIUM Vaccines comprising fliC and CD 154 polypeptides and Salmonella enteritidis vaccine vectors comprising fliC polypeptides are provided. Also provided arc methods of enhancing an immune response against flagellated bacteria and methods of reducing morbidity associa... | 06/30/2011 |
| 20110111015 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD 154 polypeptide capable of binding to CD4Q. Also provided are methods of enhancing an immune response against Ap... | 05/12/2011 |
| 20110110979 | METHOD AND VACCINE FOR OPTIMIZING THE SPECIFIC IMMUNE RESPONSES The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.... | 05/12/2011 |
| 20110064723 | Formulation for room temperature stabilization of a live attenuated bacterial vaccine This invention provides methods and compositions for stabilizing proteins and vaccines in dried formulations. In particular, a cavitation method and compositions of preparing a dried vaccine are provided that stabilize the viability of live bacteria and live virus vacci... | 03/17/2011 |
| 20110033501 | RECOMBINANT BACTERIUM CAPABLE OF ELICITING AN IMMUNE RESPONSE AGAINST ENTERIC PATHOGENS The present invention relates to a recombinant bacterium that is capable of eliciting an immune response against at least two enteric pathogens, without substantially inducing an immune response specific to the serotype of the bacterium. The invention also relates to me... | 02/10/2011 |
| 20110027309 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES Provided herein are Salmonella enteritidis 13A strains and compositions comprising these strains. Also provided are methods of enhancing an immune response against Influenza A and methods of reducing morbidity associated with an Influenza A infection. Methods of ... | 02/03/2011 |
| 20100330124 | VACCINE COMPOSITIONS AND METHODS OF USE TO PROTECT AGAINST INFECTIOUS DISEASE The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferabl... | 12/30/2010 |
| 20100285064 | ADJUVANT COMPOSITION FOR VACCINE The present invention provides a Withania somnifera fraction rich in withanolides and a vaccine comprising a “Withania somnifera fraction” as an adjuvant.... | 11/11/2010 |
| 20100284963 | GROWTH REGULATABLE RECOMBINANT BCG IMMUNOGENIC COMPOSITIONS Immunogenic compositions comprising growth regulatable recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens are provided. Exemplary immunogenic compositions include, but a... | 11/11/2010 |
| 20100278857 | Dendritic Cell Binding Proteins and Uses Thereof The present invention provides novel peptides which specifically targets and binds to dendritic cells. Also provided are fusion compositions comprising these peptides and a non-dendritic protein of fragments thereof. Further provided are DNA sequences encoding these pep... | 11/04/2010 |
| 20100272758 | Viable non-toxic gram-negative bacteria The present invention provides non-toxic Gram-negative bacteria. In particular, the present invention provides viable Gram-negative bacteria (e.g., E. coli) substantially lacking lipopolysaccharide (LPS, endotoxin) within the outer membrane. The present invention... | 10/28/2010 |
| 20100260794 | LIVE ATTENUATED SALMONELLA VACCINE The present invention relates to attenuated guaB deletion mutants of a bacterium infecting veterinary species, more in particular Salmonella enterica, to their use and production. The present invention further relates to live attenuated vaccines based on such mut... | 10/14/2010 |
| 20100255036 | ATTENUATED FNR DEFICIENT ENTEROBACTERIA The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated ent... | 10/07/2010 |
| 20100247537 | ADJUVANT COMBINATIONS OF NKT ACTIVATOR, CD40 AGONIST, AND OPTIONAL ANTIGEN, THE USE THROUGH INDUCING SYNERGISTIC CELLULAR IMMUNITY Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is als... | 09/30/2010 |
| 20100215679 | METHODS AND COMPOSITIONS FOR TREATING TULAREMIA The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach... | 08/26/2010 |
| 20100196416 | Vaccine A typhoid vaccine using heat shock protein (Hsp) of Salmonella typhi and a method for the manufacture thereof. A method of administering a composition comprising an effective amount of a complex consisting of a Hsp, in part or whole, either alone or covalently or... | 08/05/2010 |
| 20100136060 | METHODS OF REDUCING PORCINE CIRCOVIRUS-ASSOCIATED DISEASE OUTBREAKS The present invention relates to the use of an immunogenic composition that comprises a salmonella antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection, even more prefera... | 06/03/2010 |
| 20100136058 | DNA vaccines against tumor growth and methods of use thereof A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carr... | 06/03/2010 |
| 20100062019 | NEW VACCINE FORMULATIONS The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified or weakly purified. The emulsion of the present invention can act as vehicl... | 03/11/2010 |
| 20100003284 | Live attenuated aldolase-negative bacterial vaccine A live attenuated bacterium of the genus Escherichia, Salmonella or Yersinia, said bacterium being incapable of expressing a functional Eda protein as a result of a mutation in the eda gene and a vaccine comprising the live attenuated bacterium.... | 01/07/2010 |
| 20090324642 | METHOD OF ELICTING OR INDUCING AN IMMUNE RESPONSE A method for eliciting or inducing an immune response in a human or animal subject, comprises administering to said subject a composition comprising an antigen and an adjuvant, wherein the composition is administered to the subject by the intra-lung route.... | 12/31/2009 |
| 20090297561 | Method for vaccination of poultry by bacteriophage lysate bacterin The invention provides methods of generating phage lysate bacterins, as well as phage lysate bacterin compositions. The invention further encompasses methods of vaccination comprising administering phage lysate bacterin to an animal in need thereof. The invention furthe... | 12/03/2009 |
